Acquisition will bring WuXi new product lines for drug discovery and basic research, together with Abgent’s facilities in China and San Diego.
Sino-U.S. firm WuXi PharmaTech acquired Abgent, an antibody and peptide reagents firm specialized in the provision of antibody reagents for research use, therapeutic antibody development, and peptides and proteins for research and diagnostics.
WuXi claims the acquisition will provide it with new product lines for drug discovery and basic research, together with Abgent’s facilities in Suzhou, China and in San Diego. “Abgent has built a successful integrated development and production platform of catalog and customized antibody reagents for the global research reagent market,” comments Ge Li, Ph.D., WuXi chairman and CEO. “WuXi’s broad capabilities and customer relationships can take Abgent to the next level.”
WuXi is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the U.S., which provides a broad and integrated portfolio of laboratory and manufacturing services from discovery to commercialization. Its operations are divided into two segments. The laboratory services division offers a full range of discovery and development services for pharmaceuticals and biologics, along with development and testing services for biotherapeutics and medical devices, and comprehensive toxicology services. WuXi’s manufacturing services operation provides intermediates and active pharmaceutical ingredients, cell banking services, and cGMP manufacturing for cellular therapeutics and combination/tissue-based products.